Hetero USA Inc v. Merck Sharp Dohme LLC

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Hetero USA, Inc., Hetero Labs Limited Unit-III, and Hetero Labs Limited (collectively "Hetero") (Delaware and India)
  • Defendant: Merck Sharp and Dohme LLC and Merck Sharp and Dohme Corp. (collectively "Merck") (Delaware)
  • Plaintiff's Counsel: Morris James LLP; Crowell & Moring LLP
• Case Identification: 1:26-cv-00700, D. Del., 06/24/2026
• Venue Allegations: Venue is alleged to be proper as Defendants are incorporated in Delaware, conduct regular business in the state, and have previously availed themselves of the forum by filing patent infringement suits in the district.
• Core Dispute: Plaintiff seeks a declaratory judgment that its generic suvorexant tablets will not infringe two of Defendant's patents and/or that the patents are invalid.
• Technical Context: The lawsuit concerns pharmaceutical formulations of suvorexant, an orexin receptor antagonist marketed for the treatment of insomnia, focusing on methods to improve the drug's solubility and bioavailability.
• Key Procedural History: This case arises under the Hatch-Waxman Act. Hetero filed an Abbreviated New Drug Application (ANDA) seeking to market a generic version of Merck's BELSOMRA® drug, certifying under Paragraph IV that Merck's patents are invalid or not infringed. After receiving notice, Merck did not sue Hetero for infringement within the statutory 45-day window, prompting Hetero to file this declaratory judgment action to establish its right to market its product. The complaint also notes that during prosecution of the '623 patent, a terminal disclaimer was filed over the '892 patent.

Case Timeline

Date	Event
2012-05-31	Earliest Priority Date for '892 and '623 Patents
2018-10-16	'892 Patent Issued
2024-04-19	Hetero Notifies Merck of Paragraph IV Certification for '892 Patent
2024-05-14	'623 Patent Issued
2024-08-28	Hetero Notifies Merck of Paragraph IV Certification for '623 Patent
2026-06-24	Complaint for Declaratory Judgment Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,098,892 - Solid Dosage Formulations of an Orexin Receptor Antagonist (Issued October 16, 2018)

The Invention Explained

• Problem Addressed: The patent implicitly addresses the challenge of formulating suvorexant, an orexin receptor antagonist used for treating sleep disorders '892 Patent, col. 1:30-44 Like many modern drug compounds, suvorexant's therapeutic potential may be limited by poor water solubility, which can hinder its absorption in the gastrointestinal tract and reduce its bioavailability '892 Patent, abstract '892 Patent, col. 13:5-15
• The Patented Solution: The invention solves this problem by creating an "amorphous solid dispersion" of suvorexant '892 Patent, abstract It uses a "concentration-enhancing polymer," such as copovidone, to stabilize suvorexant in a non-crystalline (amorphous) state. This dispersion is prepared using a process of "hot melt extrusion" (HME), where the drug and polymer are heated and mixed to form a uniform, solid solution '892 Patent, col. 9:22-38 This amorphous form dissolves more readily in the body than the crystalline form, thereby increasing the drug's solubility and bioavailability '892 Patent, col. 3:15-31
• Technical Importance: Creating stable amorphous solid dispersions is a critical and widely used technique in modern pharmaceutics to enable the oral delivery of poorly soluble drugs.

Key Claims at a Glance

• The complaint identifies independent claims 1 and 10 as being at issue Compl. ¶49
• Independent Claim 1 Elements:
  • A pharmaceutical composition comprising: suvorexant in an amorphous form; and
  • copovidone;
  • wherein the pharmaceutical composition is prepared by a process comprising hot melt extrusion of a mixture comprising suvorexant and copovidone.
• Independent Claim 10 Elements:
  • A pharmaceutical composition comprising: suvorexant in an amorphous form;
  • copovidone;
  • lactose monohydrate;
  • microcrystalline cellulose;
  • croscarmellose sodium; and
  • magnesium stearate;
  • wherein the pharmaceutical composition is prepared by a process comprising hot melt extrusion of a mixture comprising suvorexant and copovidone.
• The complaint expressly reserves the right to assert other noninfringement positions, which may implicate dependent claims Compl. p. 13, n. 1

U.S. Patent No. 11,980,623 - Solid Dosage Formulations of an Orexin Receptor Antagonist (Issued May 14, 2024)

The Invention Explained

• Problem Addressed: The '623 patent addresses the same fundamental problem as the '892 patent: the need for a formulation that enhances the solubility and bioavailability of suvorexant for treating sleep disorders '623 Patent, col. 1:20-32
• The Patented Solution: This patent claims a pharmaceutical composition containing suvorexant in an amorphous form combined with a polymer selected from a specific group of three, which includes copovidone '623 Patent, claim 1 The claims further specify that the final composition must contain a specific dosage of suvorexant (5, 10, 15, or 20 mg) and that the suvorexant must be present in a highly pure amorphous state-"at least 90 weight % of the amorphous form ... relative to other morphological forms" '623 Patent, claim 1 The patent notes this can be achieved via processes like spray drying or hot melt extrusion '623 Patent, col. 9:30-32
• Technical Importance: The invention provides a more specific definition of the required formulation, focusing on the purity of the amorphous state and specific dosages, which can be crucial for ensuring consistent product performance and meeting regulatory standards.

Key Claims at a Glance

• The complaint identifies independent claim 1 as being at issue Compl. ¶57
• Independent Claim 1 Elements:
  • A pharmaceutical composition comprising: suvorexant in an amorphous form; and
  • a polymer selected from the group consisting of a polyvinylpyrrolidinone-polyvinyl acetate copolymer, a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, and hydroxypropyl methyl cellulose acetate succinate;
  • wherein the pharmaceutical composition comprises 5 mg, 10 mg, 15 mg or 20 mg of suvorexant; and
  • wherein the suvorexant is present in a form that contains at least 90 weight % of the amorphous form of suvorexant relative to other morphological forms of suvorexant.
• The complaint reserves the right to assert other noninfringement positions Compl. p. 15, n. 3

III. The Accused Instrumentality

Product Identification

Hetero's suvorexant tablets in 5 mg, 10 mg, 15 mg, and 20 mg dosages, for which Hetero submitted Abbreviated New Drug Application (ANDA) No. 219386 to the FDA Compl. ¶32

Functionality and Market Context

The complaint describes the products as generic equivalents to Merck's BELSOMRA® tablets Compl. ¶32 As a generic drug, it is intended to be a lower-cost alternative to the brand-name drug, with the goal of entering the market upon receiving final FDA approval Compl. ¶40 The complaint heavily redacts the specific technical details of Hetero's formulation and manufacturing process Compl. ¶¶52, 54, 60, 62 Figure 1 of the '892 patent, included as an exhibit, displays an X-ray powder diffraction (XRPD) pattern for an HME formulation, showing a broad halo without sharp peaks, which is characteristic of an amorphous material and is a key aspect of the patented technology Compl. Ex. A, FIG. 1

IV. Analysis of Infringement Allegations

The complaint, a declaratory judgment action for non-infringement, has redacted the specific technical arguments supporting Hetero's non-infringement position Compl. ¶¶52, 54, 60, 62 The unredacted text states that Hetero's ANDA Products do not literally infringe the claims of the '892 and '623 patents and also do not infringe under the doctrine of equivalents Compl. ¶¶48, 53, 55, 61 Due to the redactions, a detailed claim chart analysis is not possible.

• Identified Points of Contention:
  • Scope Questions:
    • For the '892 patent, a central question may be whether Hetero's manufacturing method falls within the scope of the claim limitation "prepared by a process comprising hot melt extrusion." Hetero may argue that its process, while achieving an amorphous dispersion, is technically distinct from the HME process as described and claimed in the patent.
    • For the '623 patent, a dispute may arise over the limitation requiring "at least 90 weight % of the amorphous form." The case could turn on the analytical methods used to measure this percentage and whether Hetero's product definitively meets this purity threshold.
  • Technical Questions: The core technical question, obscured by redactions, is how Hetero's formulation or process differs from the claimed invention. For the '892 patent, this could involve different excipients, different process parameters (e.g., temperature, screw speed), or an entirely different manufacturing technology that also produces an amorphous form. For the '623 patent, the dispute may focus on whether Hetero uses a polymer outside the claimed group of three or if its product contains a lower percentage of the amorphous form.

V. Key Claim Terms for Construction

• The Term: "prepared by a process comprising hot melt extrusion" '892 patent, claims 1 and 10

  • Context and Importance: This is a product-by-process claim limitation. Its construction is critical because infringement depends on whether Hetero's manufacturing process is the same as the one claimed, even if the final product appears similar. Practitioners may focus on this term because if Hetero uses a different, non-equivalent process, it could have a straightforward non-infringement defense.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification describes HME generally as a process where a drug and polymer are "thoroughly melted and mixed to make an amorphous dispersion" '892 Patent, col. 9:56-65 This could support a broad interpretation covering any process that melts and mixes the components.
    • Evidence for a Narrower Interpretation: The patent provides detailed examples of HME using a specific twin-screw extruder with specific temperature profiles and screw speeds '892 Patent, col. 21:35 - col. 22:50 Merck may argue that the term should be limited to processes with these or similar characteristics, as exemplified in the patent.

• The Term: "at least 90 weight % of the amorphous form of suvorexant relative to other morphological forms of suvorexant" '623 patent, claim 1

  • Context and Importance: This limitation defines a specific purity level for the amorphous drug substance. Infringement will depend on the measurement and confirmation of this percentage in Hetero's product. Practitioners may focus on this term because disputes over quantitative claim limitations often become a "battle of the experts" regarding analytical testing methodology and results.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The plain language of the claim sets a clear numerical floor. Hetero might argue that any standard, validated method for measuring crystallinity should be acceptable for determining infringement.
    • Evidence for a Narrower Interpretation: The patent specification describes specific analytical techniques for characterizing the amorphous form, including X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and Raman spectroscopy '623 Patent, col. 11:41-49 '623 Patent, col. 12:1-35 Merck could argue that the 90% threshold must be understood and measured using the specific methods disclosed and exemplified in the patent.

VI. Other Allegations

• Indirect Infringement: The complaint's prayer for relief seeks a declaration of non-infringement both directly and indirectly Compl., Prayer for Relief A Compl., Prayer for Relief C However, the body of the complaint does not provide specific facts or allegations related to indirect infringement for analysis.
• Willful Infringement: This allegation is not applicable, as this is a declaratory judgment action filed by the accused infringer.

VII. Analyst's Conclusion: Key Questions for the Case

This declaratory judgment action, prompted by Merck's decision not to sue within the Hatch-Waxman 45-day window, will center on Hetero's attempt to clear its generic suvorexant product for market entry. The case presents several central questions for the court:

1. A primary issue will be one of process versus product: For the '892 patent, can Hetero prove its manufacturing process is materially different from the claimed "hot melt extrusion" process, thereby avoiding infringement of the product-by-process claims, even if its final product is an amorphous dispersion?
2. A second key issue will be a question of quantitative proof: For the '623 patent, does Hetero's product contain less than the claimed "at least 90 weight %" of amorphous suvorexant? This will likely devolve into a technical dispute over the validity and results of the analytical methods used to measure crystallinity.
3. Finally, the case will present a significant invalidity challenge: Hetero alleges that creating an amorphous solid dispersion of suvorexant using a polymer and HME was obvious to a person of ordinary skill in the art as of May 2012 Compl. ¶¶63-67 The resolution of this claim will depend on the court's assessment of the prior art and whether the patents' claimed solutions represented a non-obvious inventive step.